RxDoctor Payments DataLook up a doctor →

Mark Galles, MD

Internal Medicine · Tulsa, OKNPI 1982681482

Payments from drug & device makers

$17,478in general payments, 2019–2025

Across 1,131 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Amgen$950
  • Lilly USA, LLC$897
  • GSK$892
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$17,392100%
  • Education$870%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)165$2,281
Novo Nordisk88$1,386
Pfizer72$1,134
Amgen61$950
Lilly USA, LLC60$897
GSK73$892
Merck63$824
Boehringer Ingelheim49$817
AstraZeneca39$711
Johnson & Johnson48$661
Astellas Pharma US Inc30$654
Abbott39$543
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC32$512
Novartis34$485
Bayer23$420
Takeda Pharmaceuticals U.S.A., Inc.23$397
Kowa Pharmaceuticals America, Inc.21$313
Amarin Pharma, Inc.18$292
Otsuka America Pharmaceutical, Inc.14$291
E.r. Squibb & Sons, L.L.C.13$185
Exact Sciences11$167
Eisai Inc.9$167
Esperion Therapeutics, Inc.8$151
Idorsia Pharmaceuticals US Inc8$150
Sanofi-aventis U.S. LLC7$121
Almatica Pharma LLC7$118
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$108
Daiichi Sankyo Inc.5$106
Teva Pharmaceuticals USA, Inc.5$95
Sumitomo Pharma America, Inc.4$95
Dexcom, Inc.4$91
Axsome Therapeutics, Inc.4$90
Arbor Pharmaceuticals, Inc.6$85
Antares Pharma, Inc.5$78
Currax Pharmaceuticals LLC5$76
Biohaven Pharmaceuticals, Inc.5$73
Scilex Pharmaceuticals Inc.5$72
Ironwood Pharmaceuticals, Inc5$72
Aimmune Therapeutics, Inc.3$71
Lundbeck LLC3$66
Boston Scientific4$64
Biohaven Pharmaceutical Holding Company Ltd.4$56
Althera Pharmaceuticals LLC4$56
Phathom Pharmaceuticals, Inc.3$51
Nabriva Therapeutics, PLC3$49
Inogen, Inc.4$49
Clarus Therapeutics Inc.3$43
Sanofi Pasteur Inc.2$41
Xeris Pharmaceuticals, Inc.2$37
Genentech USA, Inc.3$34
Regeneron Healthcare Solutions, Inc.2$34
Corium, LLC2$32
Avanir Pharmaceuticals, Inc.2$29
Nestle Healthcare Nutrition Inc.2$28
Endo Pharmaceuticals Inc.2$26
Aytu Biopharma, Inc.2$25
Azurity Pharmaceuticals, Inc.1$21
Abiomed1$20
Seqirus USA Inc1$19
Ultragenyx Pharmaceutical Inc.1$18

How this compares

$17,478 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$196,000
Medicare patients
609
Services billed
19,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$164,520
FarxigaDapagliflozin Propanediol72$106,414
OzempicSemaglutide75$93,930
JardianceEmpagliflozin76$81,338
XareltoRivaroxaban64$79,172
MounjaroTirzepatide55$61,994
TrulicityDulaglutide36$41,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$32,649
LinzessLinaclotide35$31,632
MyrbetriqMirabegron24$18,114
Breo ElliptaFluticasone/Vilanterol28$15,960
Tresiba Flextouch U-200Insulin Degludec23$15,122
Atorvastatin Calcium663$13,957
Rosuvastatin Calcium430$13,856
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide110$11,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,134$164,520163 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Brilinta$711$119,746103 claims
Lilly USA, LLCMounjaro, Trulicity$897$103,08691 claims
Novo NordiskOzempic$1,386$93,93075 claims
Boehringer IngelheimJardiance$817$81,33876 claims
Johnson & JohnsonXarelto$661$79,17264 claims
GSKTrelegy Ellipta, Breo Ellipta$892$48,60968 claims
AbbVieLinzess, Synthroid$2,281$35,608105 claims
Astellas Pharma US IncMyrbetriq$654$18,11424 claims
MerckDulera$824$5,19912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →